frequency varies among populations of different geographical and ethnic backgrounds.
Cystic fibrosis (CF) is the most common autosomal recessive
Infertility, or at least subfertility, in males with CF was first disease in Caucasians. In 97-98% of men with CF, bilateral suspected in the 1960s (Denning et al., 1968) . Infertility in congenital absence of the vas deferens (CBAVD) blocks males with CF and absence of the vas deferens originates the transport of spermatozoa resulting in azoospermia.
either as a developmental abnormality or an obstructive lesion Abnormalities in sperm parameters have also been identi- (Patrizio and Salameh, 1998) . In 97-98% of men with CF, a fied in males with CF. To date, over 800 disease-causing bilateral congenital absence of the vas deferens (CBAVD) mutations of the CF transmembrane conductance regulator blocks the transport of spermatozoa from testicular or (CFTR) gene have been identified (also called ABCC7).
epididymal structures to the outer genital tract, resulting in Current legislation suggests that prior to intracytoplasmic azoospermia.
sperm injection (ICSI) treatment, men with CBAVD or
The inheritance of CBAVD on the CF gene seems to follow unexplained oligozoospermia should be considered for simple Mendelian rules. Most male CF carriers do not have screening. If the male is negative with routine screening CBAVD. To have CBAVD, the patient has to receive two CF then the female partner is not screened. This is fundamentmutations, one from each of his parents. CF positive CBAVD ally wrong because if the female is screened and is found males always have the same heterozygous mutation as one of to be CF positive on routine testing, her partner would the two parents. Offspring of CBAVD males (with heterozygous then need the fullest possible investigation of the CFTR mutation) [following surgical sperm retrieval and intracytogene. It is ideal to screen both partners in cases of oligozoospermia. However, if the resources are stretched, plasmic sperm injection (ICSI)] have a 50% chance of having then only the female needs to be routinely screened because the same CF heterozygous mutation as the CBAVD father. if she is negative, then the couple's residual risk of having Abnormalities in semen parameters have also been identified a CF or CBAVD child will be reduced to 1:960. Only when in males with CF. They include azoospermia, reduced volume, the female is found to be a carrier does the male partner increased acidity and absent or low concentrations of fructose need routine screening followed by full testing for known (Denning et al., 1968; Kaplan et al., 1968; Rule et al., 1970; mutations. Holsclaw et al., 1971) . Not all male CF patients are infertile, Key words: assisted reproduction/cystic fibrosis/mutation/ a small percentage of them having fathered children. It is now screening believed that 2-3% of CF males are fertile (Welsh and Smith, 1995) . It was shown that at least some CF individuals carrying the 3849ϩ10kbC→T mutation are fertile and have no CBAVD (Passero, 1995; Stern et al., 1995; Dreyfus et al., 1996) . More Introduction recently, it was suggested that the frequency of CF mutations in infertile males was significantly higher than the expected Cystic fibrosis (CF) is the most common autosomal recessive CF carrier frequency in the general population (van der Ven disease in Caucasians, with a reported incidence of 1 in 2500 et al., 1996) . This increased frequency in otherwise healthy (Daigneault et al., 1992; DeBraekeleer and Daigneault, 1992;  men with reduced sperm quality and in men with azoospermia Welsh and Smith, 1995) . Statewide newborn screening prowithout CBAVD suggests that the CFTR protein could be grammes in the USA have yielded CF incidences of 1 in 2521 involved in the process of spermatogenesis or sperm maturain Colorado (Hammond et al., 1991) and 1 in 3431 in tion. It could also play a critical role in the development of Wisconsin (Gregg et al., 1993) . Based on these data, carrier frequencies can be estimated to be between 1 in 25 and 1 in 30.
the epididymis glands and the vas deferens. programme, where both parties are counselled and screened prior to treatment to provide the greatest amount of information as to treatment safety. In our unit, since the introduction of ICSI, all males with Routine screening methods have been developed for CF azoospermia due to obstruction (other than that caused by carrier detection in the general population. These methods vasectomy) or germ cell failure are routinely screened for CF usually take into account the frequency of CFTR mutations mutations. Our current protocol on CF screening involves particular to the population being studied. Around 10% of testing for eight locally common mutations (detection rate obstructive azoospermia is congenital and may be due to 90%) with further advanced testing if necessary in two stages mutations in the CF gene. It is caused by either compound up to a final detection level of 98.5% (Table II) . Following heterozygosity with at least one 'mild' mutation (10%) (Chillon this practice, we have come to question whether our screening et al., 1995) or, very occasionally, by homozygosity for two could be targeted more accurately. If the male partner proves 'mild' mutations. If 5-T tract is included as a mutation, up to to be a carrier of one of the eight CF mutations routinely 60% of CBAVD males are found to be carriers of one CF tested for, then it is an obvious requirement to screen the mutation upon routine screening (DeBraekeleer and Ferec, female partner. If the female partner proves to be negative for 1996) with presumably a rare second mutation that is not these mutations then the risk of an affected child would be included in the routine screening. Up to 20% of CBAVD 1:960 and treatment could proceed with the appropriate degree males are carriers of two different mutations (compound of counselling. As long as the female has no factors in her heterozygotes) but in these instances at least one of the CF family history that would make her at risk of carrying CF mutations is thought to have a mild effect on the clinical gene mutations, then more intense CF screening is probably phenotype. not indicated. This decision is based on risk assessment, cost and the manpower required for advanced screening and on Discussion consideration of the clinical practice in sperm donation where the female is found to be CF positive and the donor CF Genetic screening for CF carrier status was originally performed either for patients with a family history of CF, following
D.I.Lewis-Jones, M.R.Gazvani and R.Mountford associated with this highly invasive technique. One reason for
negative. Donors are only tested for the eight most common mutations in our local population as they are not at increased the birth of a CF baby or prior to the provision of sperm donation. In the latter context it was recognised that CF risk by definition for CF gene mutations. Conversely, when a CBAVD or an azoospermic male is screening could significantly reduce the risk of conceiving children with this disease bearing in mind how common the found to be CF negative on routine screening but his partner is positive then the situation is very different. The CBAVD carrier status is. With screening of donors and recipients in donor insemination clinics, the incidence of babies born with male is at risk of carrying one of the rarer CF gene mutations and therefore he should undergo advanced screening for further CF can be considerably reduced to~1:230 000. It is therefore recommended that both donor and recipient should be screened mutations, which would increase the safety of the treatment. Following further screening, the couple should be offered (Lissens et al., 1996) as this gives the greatest degree of safety (Table I) .
additional counselling before treatment is commenced and factors such as preimplantation diagnosis considered. ICSI has revolutionized the treatment of oligoasthenozoospermia (Van Steirteghem et al., 1993) . Since the first reports These two clinical scenarios provide us with a set of circumstances whereby we can look more closely at which of successful pregnancies after treatment with ICSI in humans, numerous attempts have been made to assess genetic risks partner should be given the priority regarding CF mutation Hum. Reprod., 8, [215] [216] [217] [218] [219] [220] advanced level. If the male is found to be CF positive with Retief, A.E., Van Zyl, J.A., Menkveld, R. et al. (1984) Chromosome studies routine screening, then the female must be screened for in 496 infertile males with a sperm count below 10 million/ml. Hum. common mutations and if she is negative then treatment can Genet., 66, [162] [163] [164] proceed with the necessary genetic counselling. If an oligo/ Riordan, J.R., Rommens, J.M., Kerem, B.S. et al. (1989) In conclusion, we suggest that it is crucial to screen both partners for CF mutations in couples with oligozoospermia or mutation and disease severity in cystic fibrosis. Lancet, 346, 274-276. Van der Ven, K., Messer, L., Van der Ven, H. et al. (1996) Cystic fibrosis CBAVD. However, it may be suggested that if resources are mutation screening in healthy men with reduced sperm quality. Hum.
stretched, then only the female needs to be routinely CF Reprod., 11, [513] [514] [515] [516] [517] screened because if she is negative, then the couple's residual Van Steirteghem, A.C., Nagy, Z., Joris, H. et al. (1993) does one have to check the male partner, firstly by routine mutation testing, and then by referral to a specialist centre for full investigation of the rarer CF gene mutations. It must be emphasized, however, that screening only the female will fall short in populations with a broader range of CF mutations (for instance in Southern Europe) where it would still be safer to screen both partners.
